![](/img/cover-not-exists.png)
111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY
Mufti, G.J., Best, S., Lea, N., Hellstrom-Lindberg, E., Silverman, L.R., Garcia-Manero, G., Azarnia, N., Petrone, M.E., Snyder, B.R., Gohring, G.Volume:
39
Language:
english
Journal:
Leukemia Research
DOI:
10.1016/S0145-2126(15)30112-0
Date:
April, 2015
File:
PDF, 99 KB
english, 2015